The US government has unveiled what it describes as ambitious plans to fight Alzheimer’s disease, including the development of effective prevention and treatments by 2025 ...more World News
Cost regulators for the National Health Service in England and Wales are now recommending that patients with migraines should have access to Allergan's Botox, after initially being minded to reject its use.
...more UK News
New software from imaging-data specialist AG Mednet promises to cut submission errors in clinical trials involving medical imaging and to “bring preventable delays to zero”.
...more Clinical News
The US government has unveiled what it describes as ambitious plans to fight Alzheimer’s disease, including the development of effective prevention and treatments by 2025
As world governments get ready to endorse a ten-year, $10 billion action plan for global vaccination, Medecins Sans Frontieres has expressed concern that millions of children are still not even receiving the most basic shots
Bristol-Myers Squibb has linked up with China's Tsinghua University to fund research looking at identifying new targets in oncology and immunoscience
GlaxoSmithKline is to acquire the shares it does not currently own in Anglo-German proteomics specialist Cellzome for £61 million
Pfizer has unveiled data from a late-stage trial which shows that its kidney cancer treatment Torisel failed to improve progression-free survival when compared to Bayer's rival drug Nexavar
Patients with diabetes in England are not getting the healthcare they need, with services across the country now in “a state of crisis”, UK charity Diabetes Care has warned.
One hundred and seventy-five of the pharmaceutical industry’s best medical representatives are set to attend the largest ever competency benchmarking exercise to be held in the UK next month.
NICE's final decision not to recommend Sanofi's Jevtana (cabazitaxel) for NHS use in advanced prostate cancer could herald a re-emergence of the postcode lottery, an expert has warned.
Applying a range of “highly targeted, yet complementary, push and pull delinking mechanisms” at key stages of the biopharmaceutical R&D process is the best way to tackle systemic gaps in the research and development model for neglected and tropical diseases (NTDs) and specific Type II diseases such as malaria and tuberculosis, a new report suggests.
Quanticate, the Anglo-US contract research organisation (CRO) focused mainly on data management, analysis and reporting from clinical trials, as well as post-marketing surveillance, has stepped up its presence in India by opening a new office in Bangalore.
Geoff Frew, Managing Editor
